First-pass extracted concept

gabapentinoids

Candidate: concept label1 source documents7 linked claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Gabapentinoids are presented as established first-line treatments for neuropathic pain. The review frames them as clinically important despite incomplete mechanistic understanding.

Source 1DOIPubMed

What problem it solves

They address neuropathic pain in current clinical practice where many other approaches have limited benefit.

Source 1DOIPubMed

What it does not solve

The abstract does not claim that gabapentinoids broadly solve the low overall response rate problem in neuropathic pain, and it notes that their mechanism remains poorly understood.

Source 1DOIPubMed

Alternatives

The review contrasts gabapentinoids with opioids, other therapeutic approaches with limited meaningful benefit, and emerging target-focused strategies.

Source 1DOIPubMed

Evidence Snippets

Despite this progress, the gabapentinoids retain their status as first-line treatments, yet their mechanism of action is poorly understood.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1clinical effectiveness summarysupports2018Source 1DOIPubMed

Opioids have limited effectiveness in neuropathic pain, and fewer than 35% of patients derive meaningful benefit from other therapeutic approaches.

Quoted textsource-backed
Opioids display limited effectiveness, and less than 35% of patients derive meaningful benefit from other therapeutic approaches.
Claim 2disease stage logicsupports2018Source 1DOIPubMed

Processes involved in the onset of neuropathic pain differ from those involved in its long-term maintenance.

Quoted textsource-backed
Processes involved in the onset of neuropathic pain differ from those involved in its long-term maintenance.
Claim 3drug design principlesupports2018Source 1DOIPubMed

Drugs that affect multiple processes rather than a single specific target may offer the greatest promise for future neuropathic pain therapeutic development.

Quoted textsource-backed
We suggest that drugs that affect multiple processes, rather than a single specific target, show the greatest promise for future therapeutic development.
Claim 4mechanism of action summarysupports2018Source 1DOIPubMed

Gabapentinoid interactions with the α2δ-1 subunit of voltage-gated calcium channels produce multiple neuron type-specific actions in spinal cord and higher centers.

Quoted textsource-backed
Interactions of gabapentinoids with the α2δ-1 subunit of voltage-gated Ca2+ channels produce multiple and neuron type-specific actions in spinal cord and higher centers.
Claim 5mechanistic summarysupports2018Source 1DOIPubMed

Excitatory processes are enhanced and inhibitory processes are attenuated in the spinal dorsal horn and throughout the somatosensory system, leading to central sensitization and allodynia.

Quoted textsource-backed
Excitatory processes are enhanced, and inhibitory processes are attenuated in the spinal dorsal horn and throughout the somatosensory system. This leads to central sensitization and aberrant processing such that tactile and innocuous thermal information is perceived as pain (allodynia).
Claim 6mechanistic summarysupports2018Source 1DOIPubMed

Neuropathic pain arises from many parallel, interdependent, and time-dependent processes, including neuroimmune interactions at peripheral, spinal, and supraspinal levels.

Quoted textsource-backed
Many parallel, interdependent, and time-dependent processes, including neuroimmune interactions at the peripheral, supraspinal, and spinal levels, contribute to the etiology of this "disease of pain."
Claim 7treatment status summarysupports2018Source 1DOIPubMed

Gabapentinoids remain first-line treatments for neuropathic pain, but their mechanism of action is poorly understood.

Quoted textsource-backed
Despite this progress, the gabapentinoids retain their status as first-line treatments, yet their mechanism of action is poorly understood.